You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Development of Isotopically Labeled Glycoproteins for use as Internal Standards

    SBC: GlycoScientific, L.L.C.            Topic: 300

    Project Summary/Abstract The ability to accurately quantitate the glycan chains attached to glycoproteins has wide-ranging implications. Numerous studies over the past 40 years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers, and demonstrates the potential of using glycan markers in either a diagnostic or a prognostic manner. The glycosylation on recomb ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: OD

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 999

    Abstract Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[1-4]. Hepatic fibrosis can develop in patients with any type of chronic liver disease (CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD) and autoimmune hepatitis. The major clinical consequences of cirrhosis are liver failure and hepatocellular ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of novel Amadorins for Diabetic Peripheral Neuropathy

    SBC: Praetego Inc            Topic: 200

    PROJECT SUMMARY Diabetic peripheral neuropathy (DPN) is the most common diabetic complication. DPN is a leading cause for disability due to foot ulceration and amputation, gait disturbance, and fall-related injury. There is no FDA- approved disease modifying treatment for DPN, a condition affecting up to 50% of the estimated 30 million diabetic patients in the US. Neuropathy occurs in patients wit ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Novel sanitizer/disinfectants against viral infections with long-lasting effect

    SBC: CAMELLIX, LLC            Topic: NIAID

    AbstractNorovirus is the most common cause of acute gastroenteritis in the United States, associated annually with 19-21 million illnesses, 56,000-71,000 hospitalizations and 570-800 deaths (US CDC, Overview about Norovirus). Norovirus is one of the nonenveloped viruses that are resistant to alcohol sanitization. According to US CDC Guidelines for the Prevention and Control of Norovirus Gastroente ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY Glioblastoma (GBM) is an intractable cancer with an average survival time of 12 to 15 months. Treatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrier, but engineered neural stem cells (NSCs) hold great promise as GBM therapies because they selectively migrate to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides

    SBC: Glycan Therapeutics LLC            Topic: 300

    This fast-track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates using innovative enzyme-based methods. This proposal is focused on the synthesis of large authentic oligosaccharides in the size range of 10-mers to ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infections (BSIs) caused by Gram-negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic-resistant nature of the pathogens. Infections caused by multi-drug resistant (MDR) bacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic options. This lack of treatment options is particularly ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease

    SBC: RFPi, Inc.            Topic: NHLBI

    ABSTRACT Peripheral Arterial Disease (PAD) is a substantial healthcare burden in the US (estimated andgt; 8M) and around the world (estimated andgt; 200M). In the aging population, over 24% with age andgt; 80 years have PAD. 50% of all patients with PAD are asymptomatic, and up to 40% of the remaining patients have atypical symptoms. The conventional ankle/brachial index (cABI) ratio is establishe ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Preventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring

    SBC: Infrared Rx, Inc.            Topic: NIDDK

    Preventing Vascular Complications in Type 1 Diabetes: Muscle Metabolic Monitoring Abstract Measurements of muscle metabolism and blood flow using near infrared spectroscopy (NIRS) have progressively increased, as has the number of companies selling NIRS-based devices. This technology represents the present and future modality for non-invasively characterizing normal and abnormal muscle physiology ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government